165 related articles for article (PubMed ID: 34428328)
1. Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia.
Saliba AN; Litzow MR; Gangat N; Al-Kali A; Foran JM; Hogan WJ; Palmer JM; Mangaonkar AA; Tefferi A; Patnaik MM
Am J Hematol; 2021 Nov; 96(11):E433-E436. PubMed ID: 34428328
[No Abstract] [Full Text] [Related]
2. Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series.
Garcia-Horton A; Maze D; McNamara CJ; Sibai H; Gupta V; Murphy T
Leuk Lymphoma; 2021 Jun; 62(6):1525-1527. PubMed ID: 33448888
[No Abstract] [Full Text] [Related]
3. Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.
Hammond D; Montalban-Bravo G
Curr Hematol Malig Rep; 2021 Oct; 16(5):405-417. PubMed ID: 34499330
[TBL] [Abstract][Full Text] [Related]
4. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
Montalban-Bravo G; Hammond D; DiNardo CD; Konopleva M; Borthakur G; Short NJ; Ramos-Perez J; Guerra V; Kanagal-Shamanna R; Naqvi K; Sasaki K; Jabbour E; Pemmaraju N; Kadia TM; Ravandi F; Daver N; Estrov Z; Pierce S; Kantarjian H; Garcia-Manero G
Leukemia; 2021 May; 35(5):1494-1499. PubMed ID: 33846541
[No Abstract] [Full Text] [Related]
5. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
Ball S; Jain AG; Aguirre LE; Al Ali N; Zhang Y; Chan O; Kuykendall AT; Sweet KL; Lancet JE; Swoboda DM; Padron E; Komrokji RS; Sallman DA
Am J Hematol; 2022 May; 97(5):E185-E188. PubMed ID: 35179241
[No Abstract] [Full Text] [Related]
6. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
[No Abstract] [Full Text] [Related]
8. Venetoclax and hypomethylating agent therapy for accelerated and blast phase
Yeoh ZH; Wei A
Leuk Lymphoma; 2023 Apr; 64(4):757-760. PubMed ID: 37037568
[No Abstract] [Full Text] [Related]
9. Venetoclax for Refractory Myeloid Sarcoma.
Kanate AS; Vos J; Chargualaf MJ
J Oncol Pract; 2019 Jul; 15(7):413-415. PubMed ID: 31291562
[No Abstract] [Full Text] [Related]
10. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
11. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
[No Abstract] [Full Text] [Related]
12. Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia.
Zhang T; Zhou H; Xu M; Qian C; Sun A; Wu D; Xue S
Ann Hematol; 2023 Apr; 102(4):973-975. PubMed ID: 36745193
[No Abstract] [Full Text] [Related]
13. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M; Potluri J; Choi M
Br J Haematol; 2019 Jun; 185(5):961-966. PubMed ID: 30478940
[No Abstract] [Full Text] [Related]
14. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
15. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.
Hampel PJ; Parikh SA; Call TG; Shah MV; Bennani NN; Al-Kali A; Rabe KG; Wang Y; Muchtar E; Leis JF; Kenderian SS; Koehler AB; Schwager SM; Slager SL; Kay NE; Hanson CA; Van Dyke DL; Shi M; Ding W
Blood Cancer J; 2021 Mar; 11(3):47. PubMed ID: 33654067
[No Abstract] [Full Text] [Related]
16. Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.
Benedetti E; Baratè C; Bruno B; Bramanti E; Ghia P; Scarfò L; Morganti R; Ricchiuto V; Galimberti S
Leuk Res; 2021 Jan; 100():106488. PubMed ID: 33316660
[No Abstract] [Full Text] [Related]
17. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
Jain P; Mims AS
Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
[No Abstract] [Full Text] [Related]
18. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax for the treatment of translocation (11;14) AL amyloidosis.
Sidiqi MH; Al Saleh AS; Leung N; Jevremovic D; Aljama MA; Gonsalves WI; Buadi FK; Kourelis TV; Warsame R; Muchtar E; Hobbs MA; Lacy MQ; Dingli D; Go RS; Hayman SR; Rajkumar SV; Dispenzieri A; Gertz MA; Kumar SK; Fonseca R; Kapoor P
Blood Cancer J; 2020 May; 10(5):55. PubMed ID: 32393733
[No Abstract] [Full Text] [Related]
20. Acute myeloid leukemia drug development in the post-venetoclax era.
Pollyea DA
Am J Hematol; 2019 Sep; 94(9):959-962. PubMed ID: 31179583
[No Abstract] [Full Text] [Related]
[Next] [New Search]
